Qian Ying, Hamrah Pedram, Boisgerault Florence, Yamagami Satoru, Vora Sudhir, Benichou Gilles, Dana M Reza
Department of Ophthalmology, The Schepens Eye Research Institute, Harvard Medical School, 20 Staniford Street, Boston, MA 02114, USA.
J Interferon Cytokine Res. 2002 Dec;22(12):1217-25. doi: 10.1089/10799900260475740.
This study aimed to determine the effects of anti-CD154 on T cell cytokine profiles and ocular chemokine gene expression after high-risk corneal transplantation and to specifically determine if CD154 blockade is associated with a switch from a Th1 to a Th2 alloimmune response. Mice were used as recipients of syngeneic or multiple minor H or MHC antigen-mismatched corneal grafts. Recipient beds were neovascularized (high-risk). Hosts were randomized to receive either anti-CD154 antibody or control immunoglobulin (Ig) perioperatively. Two weeks after corneal transplantation, allospecific delayed-type hypersensitivity (DTH) was evaluated. Frequencies of interferon-gamma (IFN-gamma)-, interleukin-2 (IL-2)-, IL-4-, and IL-5-secreting T cells in the hosts were measured by enzyme-linked immunospot (ELISPOT) assay. Ocular chemokine gene expression in anti-CD154-treated and control hamster Ig-treated groups was determined using a multiprobe ribonuclease protection assay (RPA). Leukocyte infiltration of corneal grafts was evaluated microscopically. Anti-CD154-treated mice did not exhibit allospecific DTH. The frequencies of Th1 cytokine-producing but not Th2 cytokine-producing T cells were significantly reduced in anti-CD154-treated hosts. Postoperative mRNA levels of RANTES and macrophage inflammatory protein-1beta (MIP-1beta) in anti-CD154-treated eyes were substantially suppressed compared with hamster Ig-treated controls. Leukocyte infiltration was profoundly suppressed in grafts of anti-CD154-treated hosts. These data demonstrate that blockade of the CD40-CD154 costimulatory pathway after corneal transplantation inhibits Th1-mediated responses but does not induce a switch to a Th2-specific response. In addition, anti-CD154 therapy suppresses ocular chemokine gene expression and leukocytic infiltration into allografts.
本研究旨在确定抗CD154对高危角膜移植术后T细胞细胞因子谱和眼内趋化因子基因表达的影响,并特别确定CD154阻断是否与同种异体免疫反应从Th1型转变为Th2型相关。将小鼠作为同基因或多个次要组织相容性抗原或主要组织相容性复合体(MHC)抗原不匹配的角膜移植受体。受体床形成了新生血管(高危)。宿主在围手术期被随机分为接受抗CD154抗体或对照免疫球蛋白(Ig)。角膜移植术后两周,评估同种异体特异性迟发型超敏反应(DTH)。通过酶联免疫斑点(ELISPOT)测定法测量宿主中分泌干扰素-γ(IFN-γ)、白细胞介素-2(IL-2)、IL-4和IL-5的T细胞频率。使用多探针核糖核酸酶保护测定法(RPA)测定抗CD154治疗组和对照仓鼠Ig治疗组的眼内趋化因子基因表达。通过显微镜评估角膜移植的白细胞浸润情况。接受抗CD154治疗的小鼠未表现出同种异体特异性DTH。在接受抗CD154治疗的宿主中,产生Th1细胞因子而非Th2细胞因子的T细胞频率显著降低。与仓鼠Ig治疗的对照组相比,抗CD154治疗眼的术后RANTES和巨噬细胞炎性蛋白-1β(MIP-1β)的mRNA水平被大幅抑制。抗CD154治疗宿主的移植物中的白细胞浸润被显著抑制。这些数据表明,角膜移植后阻断CD40-CD154共刺激途径可抑制Th1介导的反应,但不会诱导向Th2特异性反应的转变。此外,抗CD154治疗可抑制眼内趋化因子基因表达和白细胞向同种异体移植物中的浸润。